<DOC>
	<DOCNO>NCT00106054</DOCNO>
	<brief_summary>The study terminate early due low enrollment 2 subject enrol treat open enrollment year . Therefore , meaningful efficacy analysis could perform . This trial study effect ( good bad ) combination drug , Irinotecan combination infusional 5-FU , leucovorin ( FOLFIFI ) plus Bevacizumab , cancer colon rectum spread liver currently able remove surgery . All drug receive research study approve United States colorectal cancer , spread area body , include liver . Another reason study see chemotherapy drug FOLFIFI plus Bevacizumab sufficiently decrease size cancer liver tumor remain completely remove surgery , remove whether prolong time take cancer return and/or prolong life patient . This trial also look gene people take part study , see possible find characteristic help predict whose cancer respond well well , less side effect chemotherapy .</brief_summary>
	<brief_title>Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>ECOG performance status 0 1 Histological documentation adenocarcinoma colon rectum . The primary site must confirm large bowel Prior systemic anticancer therapy mCRC Prior hepatic surgery , chemoembolization , hepatic artery infusion , radiofrequency ablation cryotherapy liver metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>